MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer

Science Signaling

Volumn 7, Issue 336, 2014, Pages

  Thirumurthi, Umadevi ^a,b   Shen, Jia ^a,b   Xia, Weiya ^a   LaBaff, Adam M ^a,b,h   Wei, Yongkun ^a   Li, Chia Wei ^a   Chang, Wei Chao ^c   Chen, Chung Hsuan ^d,e,f   Lin, Hui Kuan ^a,b   Yu, Dihua ^a,b   Hung, Mien Chie ^a,b,c,g  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d GENOMICS RESEARCH CENTER   (Taiwan)

^e INSTITUTE OF ATOMIC AND MOLECULAR SCIENCES   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g ASIA UNIVERSITY   (Taiwan)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B; PROTEIN MDM2; SERINE; SIRTUIN 6; TRASTUZUMAB; AKT1 PROTEIN, HUMAN; AKT1 PROTEIN, MOUSE; ANTINEOPLASTIC AGENT; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; SIRT6 PROTEIN, HUMAN; SIRT6 PROTEIN, MOUSE; SIRTUIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST TUMOR; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UBIQUITINATION; ANIMAL; CELL PROLIFERATION; DRUG RESISTANCE; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; HELA CELL LINE; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HELA CELLS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; SIRTUINS;

EID: 84925729166     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005076     Document Type: Article

References (42)

1. T. Finkel, C. X. Deng, R. Mostoslavsky, Recent progress in the biology and physiology of sirtuins. Nature 460, 587-591 (2009).
2. R. Mostoslavsky, K. F. Chua, D. B. Lombard, W.W. Pang, M. R. Fischer, L. Gellon, P. Liu, G. Mostoslavsky, S. Franco, M. M. Murphy, K. D. Mills, P. Patel, J. T. Hsu, A. L. Hong, E. Ford, H. L. Cheng, C. Kennedy, N. Nunez, R. Bronson, D. Frendewey, W. Auerbach, D. Valenzuela, M. Karow, M. O. Hottiger, S. Hursting, J. C. Barrett, L. Guarente, R. Mulligan, B. Demple, G. D. Yancopoulos, F.W. Alt, Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124, 315-329 (2006).
3. E. Michishita, R. A. McCord, E. Berber, M. Kioi, H. Padilla-Nash, M. Damian, P. Cheung, R. Kusumoto, T. L. A. Kawahara, J. C. Barrett, H. Y. Chang, V. A. Bohr, T. Ried, O. Gozani, K. F. Chua, SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452, 492-496 (2008).
4. H. S. Kim, C. Xiao, R. H. Wang, T. Lahusen, X. Xu, A. Vassilopoulos, G. Vazquez-Ortiz, W. I. Jeong, O. Park, S. H. Ki, B. Gao, C. X. Deng, Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 12, 224-236 (2010).
5. C. Xiao, H. S. Kim, T. Lahusen, R. H.Wang, X. Xu, O. Gavrilova, W. Jou, D. Gius, C. X.Deng, SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J. Biol. Chem. 285, 36776-36784 (2010).
6. L. Zhong, A. D'Urso, D. Toiber, C. Sebastian, R. E. Henry, D. D. Vadysirisack, A. Guimaraes, B. Marinelli, J. D. Wikstrom, T. Nir, C. B. Clish, B. Vaitheesvaran, O. Iliopoulos, I. Kurland, Y. Dor, R. Weissleder, O. S. Shirihai, L. W. Ellisen, J. M. Espinosa, R. Mostoslavsky, The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1a. Cell 140, 280-293 (2010).
7. A. Kaidi, B. T. Weinert, C. Choudhary, S. P. Jackson, Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science 329, 1348-1353 (2010).
8. Z. Y. Mao, C. Hine, X. Tian, M. Van Meter, M. Au, A. Vaidya, A. Seluanov, V. Gorbunova, SIRT6 promotes DNA repair under stress by activating PARP1. Science 332, 1443-1446 (2011).
9. R. A. McCord, E. Michishita, T. Hong, E. Berber, L. D. Boxer, R. Kusumoto, S. H. Guan, X. B. Shi, O. Gozani, A. L. Burlingame, V. A. Bohr, K. F. Chua, SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging 1, 109-121 (2009).
10. E. Michishita, R. A. McCord, L. D. Boxer, M. F. Barber, T. Hong, O. Gozani, K. F. Chua, Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle 8, 2664-2666 (2009).
11. R. I. Tennen, D. J. Bua, W. E. Wright, K. F. Chua, SIRT6 is required for maintenance of telomere position effect in human cells. Nat. Commun. 2, 433 (2011).
12. B. Yang, B. M. M. Zwaans, M. Eckersdorff, D. B. Lombard, The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic stability. Cell Cycle 8, 2662-2663 (2009).
13. L. H. Min, Y. Ji, L. Bakiri, Z. X. Qiu, J. Cen, X. T. Chen, L. L. Chen, H. Scheuch, H. Zheng, L. X. Qin, K. Zatloukal, L. J. Hui, E. F. Wagner, Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell Biol. 14, 1203-1211 (2012).
14. C. Sebastián, B. M. M. Zwaans, D. M. Silberman, M. Gymrek, A. Goren, L. Zhong, O. Ram, J. Truelove, A. R. Guimaraes, D. Toiber, C. Cosentino, J. K. Greenson, A. I. MacDonald, L.McGlynn, F. Maxwell, J. Edwards, S. Giacosa, E. Guccione, R. Weissleder, B. E. Bernstein, A. Regev, P. G. Shiels, D. B. Lombard, R. Mostoslavsky, The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151, 1185-1199 (2012).
15. S. Oesterreich, D. C. Allredl, S. K. Mohsin, Q. Zhang, H.Wong, A. V. Lee, C. K. Osborne, P. O'Connell, High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br. J. Cancer 84, 493-498 (2001).
16. S. B. Sobottka, M. Haase, G. Fitze, M. Hahn, H. K. Schackert, G. Schackert, Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J. Neurooncol. 49, 187-195 (2000).
17. T. L. Yang, Y. R. Su, C. S. Huang, J. C. Yu, Y. L. Lo, P. E. Wu, C. Y. Shen, High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity. Gene Chromosomes Cancer 41, 250-256 (2004).
18. Y. V. Miteva, I. M. Cristea, A proteomic perspective of Sirtuin 6 (SIRT6) phosphorylation and interactions and their dependence on its catalytic activity. Mol. Cell. Proteomics 13, 168-183 (2014).
19. Z. Lin, H. Yang, C. Tan, J. Li, Z. Liu, Q. Quan, S. Kong, J. Ye, B. Gao, D. Fang, USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation. Cell Rep. 5, 1639-1649 (2013).
20. J. Guevara-Aguirre, P. Balasubramanian, M. Guevara-Aguirre, M. Wei, F. Madia, C. W. Cheng, D. Hwang, A. Martin-Montalvo, J. Saavedra, S. Ingles, R. de Cabo, P. Cohen, V. D. Longo, Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 3, 70ra13 (2011).
21. Y. Kanfi, S. Naiman, G. Amir, V. Peshti, G. Zinman, L. Nahum, Z. Bar-Joseph, H. Y. Cohen, The sirtuin SIRT6 regulates lifespan in male mice. Nature 483, 218-221 (2012).
22. T. L. A. Kawahara, E. Michishita, A. S. Adler, M. Damian, E. Berber, M. Lin, R. A. McCord, K. C. L. Ongaigui, L. D. Boxer, H. Y. Chang, K. F. Chua, SIRT6 links histone H3 lysine 9 deacetylation to NF-κB-dependent gene expression and organismal life span. Cell 136, 62-74 (2009).
23. N. R. Sundaresan, P. Vasudevan, L. Zhong, G. Kim, S. Samant, V. Parekh, V. B. Pillai, P. V. Ravindra, M. Gupta, V. Jeevanandam, J. M. Cunningham, C. X. Deng, D. B. Lombard, R. Mostoslavsky, M. P. Gupta, The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat. Med. 18, 1643-1650 (2012).
24. F. Chang, J. T. Lee, P. M. Navolanic, L. S. Steelman, J. G. Shelton, W. L. Blalock, R. A. Franklin, J. A. McCubrey, Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia 17, 590-603 (2003).
25. C. L. Hu, R. G. Cowan, R. M. Harman, S. M. Quirk, Cell cycle progression and activation of Akt kinase are required for insulin-like growth factor I-mediated suppression of apoptosis in granulosa cells. Mol. Endocrinol. 18, 326-338 (2004).
26. O. Larsson, A. Girnita, L. Girnita, Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer 92, 2097-2101 (2005).
27. B. P. Zhou, Y. Liaq, W. Y. Xia, Y. Y. Zou, B. Spohn, M. C. Hung, HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3, 973-982 (2001).
28. M. Ashcroft, R. L. Ludwig, D. B. Woods, T. D. Copeland, H. O. Weber, E. J. MacRae, K. H. Vousden, Phosphorylation of HDM2 by Akt. Oncogene 21, 1955-1962 (2002).
29. R. Honda, H. Yasuda, Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19, 1473-1476 (2000).
30. R. Nahta, D. Yu, M. C. Hung, G. N. Hortobagyi, F. J. Esteva, Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 3, 269-280 (2006).
31. Q. B. She, S. Chandarlapaty, Q. Ye, J. Lobo, K. M. Haskell, K. R. Leander, D. DeFeo-Jones, H. E. Huber, N. Rosen, Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLOS One 3, e3065 (2008).
32. S. Chandarlapaty, R. A. Sakr, D. Giri, S. Patil, A. Heguy, M. Morrow, S. Modi, L. Norton, N. Rosen, C. Hudis, T. A. King, Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin. Cancer Res. 18, 6784-6791 (2012).
33. P. Grell, P. Fabian, M. Khoylou, L. Radova, O. Slaby, R. Hrstka, R. Vyzula, M. Hajduch, M. Svoboda, Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Int. J. Oncol. 41, 1204-1212 (2012).
34. C. H. Chan, C. F. Li, W. L. Yang, Y. Gao, S. W. Lee, Z. Z. Feng, H. Y. Huang, K. K. C. Tsai, L. G. Flores, Y. P. Shao, J. D. Hazle, D. H. Yu, W. Y. Wei, D. Sarbassov, M. C. Hung, K. I. Nakayama, H. K. Lin, The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, Herceptin sensitivity, and tumorigenesis. Cell 149, 1098-1111 (2012).
35. A. Gallardo, E. Lerma, D. Escuin, A. Tibau, J. Muñoz, B. Ojeda, A. Barnadas, E. Adrover, L. Sánchez-Tejada, D. Giner, F. Ortiz-Martínez, G. Peiró, Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br. J. Cancer 106, 1367-1373 (2012).
36. S. M. Ronnebaum, Y. Wu, H. McDonough, C. Patterson, The ubiquitin ligase CHIP prevents SirT6 degradation through noncanonical ubiquitination. Mol. Cell. Biol. 33, 4461-4472 (2013).
37. J. Yuan, K. Luo, L. Zhang, J. C. Cheville, Z. Lou, USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384-396 (2010).
38. R. Nahta, R. M. O'Regan, Evolving strategies for overcoming resistance to HER2-directed therapy: Targeting the PI3K/Akt/mTOR pathway. Clin. Breast Cancer 10 (Suppl. 3), S72-S78 (2010).
39. S. Zhang, W. C. Huang, P. Li, H. Guo, S. B. Poh, S. W. Brady, Y. Xiong, L. M. Tseng, S. H. Li, Z. Ding, A. A. Sahin, F. J. Esteva, G. N. Hortobagyi, D. Yu, Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 17, 461-469 (2011).
40. T. T. Junttila, R.W. Akita, K. Parsons, C. Fields, G. D. L. Phillips, L. S. Friedman, D. Sampath, M. X. Sliwkowski, Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15, 429-440 (2009).
41. K. A. Poon, K. Flagella, J. Beyer, J. Tibbitts, S. Kaur, O. Saad, J. H. Yi, S. Girish, N. Dybdal, T. Reynolds, Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol. Appl. Pharmacol. 273, 298-313 (2013).
42. W. Xia, Y. Wei, Y. Du, J. Liu, B. Chang, Y. L. Yu, L. F. Huo, S. Miller, M. C. Hung, Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol. Carcinog. 48, 610-617 (2009).